The patent's assignee for patent number 8790715 is
News editors obtained the following quote from the background information supplied by the inventors: "The administration of nitric oxide (NO) gas via inhalation for treating patients with pulmonary hypertension is described in Zapol and Frostell's U.S. Pat. No. 5,485,827 'Methods and Devices for Treating Pulmonary Vasoconstriction and Asthma'.
"At the present, nitric oxide gas is commonly used for the treatment of persistent pulmonary hypertension in the newborn and is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure (HRF) associated with clinical or echocardiographic evidence of pulmonary hypertension. In babies with HRF, blood vessels in the lungs constrict, making it difficult for the heart to pump blood through the lungs for oxygenation. Nitric oxide is a pulmonary vasodilator, which relaxes the blood vessels of the lungs in newborns whose heart and lungs could not otherwise carry enough oxygenated blood to the body tissues.
"There are also other clinical applications in which NO is used to treat surface infections on the skin of a patient as described in U.S. Pat. No. 6,432,077.
"U.S. Pat. No. 5,670,127 'Process for the Manufacture of Nitric Oxide' (
"Nitric oxide readily combines with oxygen (O.sub.2) to form nitrogen dioxide (NO.sub.2), a known toxic gas, so it is very important that the gas cylinder does not become contaminated with oxygen. It is for this reason that the diluent gas used in the cylinders is one that is inert to, i.e. will not oxidize, nitric oxide. While a number of such inert gases are known, it is preferred to utilize nitrogen, N.sub.2, primarily on the basis of cost.
"The delivery apparatus for dispensing gaseous NO has to deliver the NO source gas into the patient's respirable gas to give a concentration in the range of 1-80 ppm to the patient's lung in a precise and controllable manner. It also has to deliver it in a manner that minimizes the formation of NO.sub.2. The parameters that are relevant to the formation of NO.sub.2 are the square of the NO concentration, the O.sub.2 concentration and the time for the reaction between them to take place. The O.sub.2 concentration is not normally controllable by the NO delivery device and the source gas is at a fixed concentration, therefore, the time for the reaction to take place is the only variable.
"Apparatus for the delivery of nitric oxide (NO) from a gas cylinder has to not only precisely deliver the correct dose of NO to the patient, but also to minimize the time from delivery to when the patient breathes in the gas to prevent the formation of NO.sub.2 at unsafe levels. An example of a bedside NO delivery device that achieves these two functions is described in U.S. Pat. No. 5,558,083 which shows how a constant concentration of NO can be delivered to a patient who is on a gas delivery system such as a ventilator. Smaller ambulatory NO delivery devices are described in U.S. Pat. No. 6,089,229, U.S. Pat. No. 6,109,260, U.S. Pat. No. 6,125,846, and U.S. Pat. No. 6,164,276, which describe how dosing can be provided in a pulse mode while keeping NO.sub.2 levels at an acceptably low level. While these pulse devices allow a compact and low weight delivery device to be made, they still require the bulk and weight of the NO cylinder for NO to be delivered.
"Because of the challenges surrounding the current method of producing, distributing and safely administrating nitric oxide from pressurized cylinders to a patient, there have been a number of alternate solutions proposed to generate NO locally and to immediately deliver it to the patient. Some of those alternate solutions include using an electric arc discharge to produce NO from air prior to delivering it to a patient (U.S. Pat. No. 5,396,882): producing NO for inhalation by establishing a coulometric reduction of copper ions in a solution of nitric acid along with purging the chamber with an inert gas (U.S. Pat. No. 5,827,420); using a corona discharge to generate NO in a chamber that contains oxygen and nitrogen (EP 0719159); using a plasma chemical reaction method while heating the reaction chamber to 400-800.degree. C. to obtain high efficiency of NO production (U.S. Pat. No. 6,296,827); and using heat to break down an organic nitrogen-containing compound, such as ammonia, to form NO (U.S. Pat. No. 6,758,214).
"Each of the proposed solutions, however, has certain drawbacks in the generation of NO for direct delivery to the patient rather than having to handle the bulk and weight of pressurized gas cylinders and all of the proposed solutions fail to meet at least one of the requirements for a successful portable and safe NO generation system for the immediate delivery of NO to a patient. These requirements can include (1) compact size for easy handling (
"Accordingly, it would be advantageous to have a method and device for the local generation of NO for immediate delivery to the patient and which overcomes the drawbacks and difficulties of the prior attempted solutions and which also possesses all of the desirable characteristics of such a system."
As a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors' summary information for this patent: "This invention describes methods and devices for the local generation of NO for immediate delivery to a patient that is compact, low weight, requires no toxic reactant compounds, uses low electrical power and provides fast and controllable NO generation. A general aspect of the invention is a method for producing nitric oxide (NO) for the immediate delivery to a mammal, i.e. human or animal by bringing together controllable quantities of a nitrite salt, preferably sodium nitrite, and a reductant, preferably at least one of ascorbic acid and maleic acid, in the presence of water in the desired quantities to produce the amount of NO required by the mammal and for the NO to then be immediately delivered to the mammal. Preferably, NO produced in accordance with the present invention is delivered for inhalation by the mammal. By generating the NO within the apparatus immediately prior to delivering it to the mammal, the time for NO.sub.2 formation is kept to a minimum. These and other features and advantages of the present invention will become more readily apparent during the following detailed description taken in conjunction with the drawings herein."
For additional information on this patent, see:
Keywords for this news article include: Chemicals, Chemistry, Nitric Acid, Nitric Oxide, Nitrogen Oxides,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- PBS Series Examines America's Demographic Shift
- Americans Bet Big on Gambling Industry
- Exxon Gives Nod to Fracking Risks
- Can You Be Fired for Using Medical Marijuana?
- California's Ban on Plastic Bags: What Now?
- Wealth Gap Widens as Rich Spend More on Kids' Education
- Texas Sees Gains in Hispanic College Enrollment
- Petri Likely Broke House Ethics Rules
- Morgan: 'Can't Believe' Wal-Mart Blaming Him
- Lack of Sea Ice Brings 35,000 Walruses Ashore